We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Octopus Group

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Biomarker Identified in Breast and Prostate Cancers

By LabMedica International staff writers
Posted on 25 Aug 2015
Print article
Image: The LTQ Orbitrap Elite mass spectrometer (Photo courtesy of Thermo Scientific).
Image: The LTQ Orbitrap Elite mass spectrometer (Photo courtesy of Thermo Scientific).
A novel genetic biomarker has been identified responsible for the progression of many breast and prostate cancers and these finding could bolster efforts to better identify patients who respond to certain types of chemotherapy drugs that attack the most aggressive forms of cancer.

Metastatic dissemination is a multistep process that involves cell migration, invasion and growth at distant sites and the “amoeboid” phenotype has emerged as a migratory mechanism that facilitates metastasis. Amoeboid behavior is prominent at the invasive front of tumors, confers rapid migration rates and enables survival within the vasculature.

Scientists at Cedars-Sinai Medical Center (Los Angeles, CA, USA) and their colleagues investigated whether the loss of Diaphanous-related formin-3 (DIAPH3), frequently associated with metastatic breast and prostate cancers, correlates with increased sensitivity to taxanes, which are widely employed chemotherapies for patients with metastatic prostate and breast cancer.

Different patient cohorts were analyzed for DIAPH3 gene expression profiles and various other techniques were used in the study. These included the identification of DIAPH3 interactomes where tryptic peptides were extracted, concentrated, reconstituted in 0.1% formic acid, separated on a 25 cm EASY-Spray C18 column, and analyzed by an LTQ Orbitrap Elite mass spectrometer (Thermo Scientific; Waltham, MA, USA). Live cells were imaged using a Nikon Ti inverted confocal microscope (Nikon Instruments Inc.; Melville, NY, USA) coupled to a Spinning Disk head (Yokogawa Electric Corporation; Tokyo, Japan).

The scientists found that that loss of DIAPH3, frequently associated with metastatic breast and prostate cancers, correlated with increased sensitivity to taxanes. DIAPH3 interacted with microtubules (MT), and its loss altered several parameters of MT dynamics as well as decreased polarized force generation, contractility, and response to substrate stiffness. Silencing of DIAPH3 increased the cytotoxic response to taxanes in prostate and breast cancer cell lines. Analysis of drug activity for tubulin-targeted agents in the NCI-60 cell line panel revealed a uniform positive correlation between reduced DIAPH3 expression and drug sensitivity. Low DIAPH3 expression correlated with improved relapse-free survival in breast cancer patients treated with chemotherapeutic regimens containing taxanes.

Shlomo Melmed, MD, director of the Burns and Allen Research Institute at Cedar-Sinai, said, “By identifying cancer biomarkers, then customizing treatment plans for individuals based on this genetic information, we can greatly improve the effectiveness of cancer therapies. This customized plan replaces a one-size-fits-all approach to cancer treatment.” The study was published online on July 16, 2015, in the journal Scientific Reports.

Related Links:

Cedars-Sinai Medical Center
Thermo Scientific 
Nikon Instruments Inc.


New
Gold Supplier
Multichannel Pipettes
Finnpipette Novus
New
Infection Laboratory Test Panels
Synovasure
New
Liquid Urinalysis Control
URiTROL
New
Respiratory Syncytial Virus PCR Test
WizDx RSV CrystalMix PCR Kit

Print article

Channels

Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more

Molecular Diagnostics

view channel
Image: The new assay enables accurate prognosis and detection data for those prone to esophageal cancer (Photo courtesy of Previse)

First-of-Its-Kind Test Helps Determine Future Risk of Esophageal Cancer

Esophageal cancer is among the most lethal cancers in the world and has a 20% five-year survival rate post-diagnosis. Barrett's esophagus is the sole precursor known and is a significant risk factor for... Read more

Immunology

view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more

Microbiology

view channel
Image: Sampling a single stool using multiple PCR panels can identify more pathogens rapidly (Photo courtesy of Pexels)

PCR Panels for Acute GI Infections Can Lower Costs, Hospitalization and Antibiotic Use

Acute gastroenteritis impacts adults across all age groups and incurs enormous healthcare expenses. Now, a new study comprising 40,000 hospital visits across various geographic locations has revealed that... Read more

Technology

view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more

Industry

view channel
Image: Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel (Photo courtesy of Roche)

Roche and Eli Lilly Collaborate on Innovative Blood Test for Early Diagnosis of Alzheimer's

Presently, obstacles to timely and precise diagnosis of Alzheimer's disease exist globally, resulting in as many as 75% of individuals exhibiting symptoms but lacking a formal diagnosis.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.